Key features and details
- FITC Rabbit polyclonal to Vaccinia Virus
- Suitable for: ICC/IF
- Reacts with: Vaccinia virus
- Conjugation: FITC. Ex: 493nm, Em: 528nm
- Isotype: IgG
Product nameFITC Anti-Vaccinia Virus antibody
See all Vaccinia Virus primary antibodies
DescriptionFITC Rabbit polyclonal to Vaccinia Virus
ConjugationFITC. Ex: 493nm, Em: 528nm
SpecificityAb19970 recognizes purified virions.
Tested applicationsSuitable for: ICC/IFmore details
Species reactivityReacts with: Vaccinia virus
Tissue, cells or virus corresponding to Vaccinia Virus. Lister strain (mixture of virions and infected cell polypeptides)
IgG fraction covalently coupled with high purity Isomer I of fluorescein isothiocyanate.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Storage instructionsShipped at 4°C. Store at +4°C.
Storage bufferPreservative: 0.1% Sodium azide
Constituents: 0.0268% PBS, 1% BSA
Concentration information loading...
PurityProtein A purified
Purification notesCare is taken to ensure complete removal of any free fluorescein from the final product.
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab19970 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use at an assay dependent dilution.
Use at an assay dependent dilution.
RelevanceVaccinia virus is an Orthopoxvirus, containing double stranded DNA. Fusion protein plays an important role in the entry of enveloped virus into cells. As vaccinia virus has a wide host range, it is conceivable that certain cellular components that are ubiquitously expressed on the cell mediate virus infection. The study of the entry process, attachment, fusion and the proteins and receptors involved is complex. During vaccinia virus infection, the fusion process is attributed to the action of the 14KDa protein (A27L). The N terminus of this protein recognises heparan sulfate on the cell surface. It interacts with the negative charges of sulfates of glycosaminoglycans (GAGs). Therefore, antibodies that recognize this 14KDa protein are able to neutralize vaccinia virus infection and enable identification other viral and cellular proteins which participate in the vaccinia virus entry process.
- A27L antibody
- Orthopoxvirus antibody
ab19970 has been referenced in 4 publications.
- Chen W et al. Gemcitabine combined with an engineered oncolytic vaccinia virus exhibits a synergistic suppressive effect on the tumor growth of pancreatic cancer. Oncol Rep 41:67-76 (2019). PubMed: 30365143
- Lauron EJ et al. Viral MHCI inhibition evades tissue-resident memory T cell formation and responses. J Exp Med 216:117-132 (2019). PubMed: 30559127
- Hou W et al. Oncolytic vaccinia virus demonstrates antiangiogenic effects mediated by targeting of VEGF. Int J Cancer 135:1238-46 (2014). PubMed: 24474587
- Li Z et al. A flow cytometry-based immuno-titration assay for rapid and accurate titer determination of modified vaccinia Ankara virus vectors. J Virol Methods 169:87-94 (2010). PubMed: 20637240